Provided by Tiger Trade Technology Pte. Ltd.

Tema Heart & Health ETF

35.80
-0.0478-0.13%
Post-market: 35.68-0.1239-0.35%19:30 EDT
Volume:1K
Turnover:45.58K
Market Cap:52.99M
PE:- -
High:35.80
Open:35.68
Low:35.68
Close:35.85
52wk High:38.87
52wk Low:31.87
Shares:1.48M
Float Shares:1.48M
Volume Ratio:0.73
T/O Rate:0.09%
Dividend:0.47
Dividend Rate:1.32%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Jefferies Adjusts Price Target on Merck & Co to $177 From $175, Keeps Buy Rating

MT Newswires Live
·
Oct 01

Lilly Says Foundayo Cuts Predicted 10-Year Type 2 Diabetes Risk 57% in Attain-1 Post-Hoc Analysis

Reuters
·
Oct 01

Eli Lilly - Foundayo 17.2 Mg Associated with 57% Reduction in Diabetes Risk, 18% in Cardiovascular Risk Versus Placebo

Reuters
·
Oct 01

Eli Lilly - Foundayo Associated with Reduced Predicted Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease

THOMSON REUTERS
·
Oct 01

UnitedHealth - 95% of Medicare-Eligible Individuals to Have Access to Hmo Plan in 2027

THOMSON REUTERS
·
Oct 01

Unitedhealthcare 2027 Medicare Plans Focus on Affordability, Simplicity and a More Connected Healthcare Experience

THOMSON REUTERS
·
Oct 01

Unitedhealthcare: 2027 Plans Offer $0 Primary Care Visits, $0 Preventive Care, $0 Tier 1 Drug Copays

THOMSON REUTERS
·
Oct 01

Unitedhealthcare: Introduces 2027 Medicare Advantage Plans; About 90% of Eligible Consumers to Have Access to $0 Premium

THOMSON REUTERS
·
Oct 01

UnitedHealthcare, Aetna Say 2027 Medicare Advantage Plans to Offer More Limited Provider Networks

Reuters
·
Oct 01

Merck Schedules Third-Quarter Sales and Earnings Conference Call with Investors and Analysts

Reuters
·
Oct 01

Should CHO K1 Media Launch Require Action From Thermo Fisher Scientific Stock Investors?

Simply Wall St.
·
Oct 01

Merck & Co Inc : Jefferies Raises Target Price to $177 from $175

THOMSON REUTERS
·
Oct 01

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Oct 01

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
Oct 01

Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial

Dow Jones
·
Oct 01

Eli Lilly’s Foundayo shows cardiovascular safety in type 2 diabetes study

TIPRANKS
·
Oct 01

Lilly's Oral Glp-1, Foundayo (Orforglipron), Demonstrated Cardiovascular Safety Alongside Sustained A1c Reduction and Weight Loss in Its Largest and Longest Type 2 Diabetes Study

THOMSON REUTERS
·
Oct 01

Eli Lilly - Achieve-4: Foundayo Shows 16% Lower Mace-4 and 23% Lower Mace-3 Risk vs Insulin Glargine

THOMSON REUTERS
·
Oct 01

Eli Lilly - Foundayo Shows Smaller Egrf Reduction and Greater Albuminuria Reduction vs Insulin Glargine

THOMSON REUTERS
·
Oct 01

Agilent Technologies Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01